Complexes of metals other than platinum as antitumour agents View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-08

AUTHORS

P. Köpf-Maier

ABSTRACT

The earliest reports on the therapeutic use of metals or metal-containing compounds in cancer and leukemia date from the sixteenth and nineteenth centuries. They were forgotten until the 1960s, when the antitumour activity of the inorganic complex cis-diammine-dichloroplatinum(II) (cisplatin) was discovered. This led to the development of other types of non-organic cytostatic drugs.Cisplatin has developed into one of the most frequently used and most effective cytostatic drugs for the treatment of solid carcinomas. Numerous other metal compounds containing platinum, other platinum metals, and even non-platinum metals were then shown to be effective against tumours in man and experimental tumours in animals. These compounds comprise main-group metallic compounds of gallium, germanium, tin, and bismuth, early-transition metal complexes of titanium, vanadium, niobium, molybdenum, and rhenium, and late-transition metal complexes of ruthenium, rhodium, iridium, platinum, copper, and gold.Several platinum complexes and four non-platinum-metal antitumour agents have so far entered early clinical trials. Gallium trinitrate and spirogermanium have already passed phase II clinical studies and have shown limited cytostatic activity against certain human carcinomas and lymphomas. The two early-transition metal complexes budotitane and titanocene dichloride have just reached the end of phase I clinical trials and have been found to have an unusual pattern of organ toxicity in man. Titanocene dichloride will soon enter phase II clinical studies. More... »

PAGES

1-16

References to SciGraph publications

  • 1985-09. A phase II study of spirogermanium in patients with metastatic malignant melanoma in INVESTIGATIONAL NEW DRUGS
  • 1988-10. Antitumor properties of organometallic metallocene complexes of tin and germanium in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1988. Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity in BIOINORGANIC CHEMISTRY
  • 1988. Transition and main-group metal cyclopentadienyl complexes: Preclinical studies on a series of antitumor agents of different structural type in BIOINORGANIC CHEMISTRY
  • 1991. Tumor-inhibiting bis(β-Diketonato) metal complexes. Budotitane, cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV) in BIOINORGANIC CHEMISTRY
  • 1992-03. Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1989. Ruthenium Chemistry Pertaining to the Design of Anticancer Agents in RUTHENIUM AND OTHER NON-PLATINUM METAL COMPLEXES IN CANCER CHEMOTHERAPY
  • 1989-07. Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1989-07. Phase II evaluation of gallium nitrate by continuous infusion in breast cancer in INVESTIGATIONAL NEW DRUGS
  • 1994. Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes — early transition metal antitumour drugs in METAL COMPOUNDS IN CANCER THERAPY
  • 1969-04. Platinum Compounds: a New Class of Potent Antitumour Agents in NATURE
  • 1987-07. Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1992-09. Ionic rhenocene derivatives with antitumor activity in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1989-10. Effects of two pyridinalalkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1991-10. Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991 in BRITISH JOURNAL OF CANCER
  • 1984-11. Ferricenium complexes: A new type of water-soluble antitumor agent in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1987-08. Efficacy of β-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1991-08. Gallium Nitrate in DRUGS
  • 1989. Chemical, Biological and Antitumor Properties of Ruthenium(II) Complexes with Dimethylsulfoxide in RUTHENIUM AND OTHER NON-PLATINUM METAL COMPLEXES IN CANCER CHEMOTHERAPY
  • 1989. Radioruthenium-Labeled Compounds for Diagnostic Tumor Imaging in RUTHENIUM AND OTHER NON-PLATINUM METAL COMPLEXES IN CANCER CHEMOTHERAPY
  • 1983-09. Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity in INVESTIGATIONAL NEW DRUGS
  • 1986-06. Pattern of toxicity by titanocene dichloride in mice in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1989-07. Ionic titanocene complexes: a new type of antitumor agent in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf00193472

    DOI

    http://dx.doi.org/10.1007/bf00193472

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1007044066

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/7988618


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase I as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase II as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "In Vitro Techniques", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Metals", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Institut f\u00fcr Anatomie, Freie Universit\u00e4t Berlin, D-14195, Berlin-Dahlem, Germany", 
              "id": "http://www.grid.ac/institutes/grid.14095.39", 
              "name": [
                "Institut f\u00fcr Anatomie, Freie Universit\u00e4t Berlin, D-14195, Berlin-Dahlem, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "K\u00f6pf-Maier", 
            "givenName": "P.", 
            "id": "sg:person.0113514530.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0113514530.30"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/222385a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001455608", 
              "https://doi.org/10.1038/222385a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01410137", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041980973", 
              "https://doi.org/10.1007/bf01410137"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1991.400", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015978323", 
              "https://doi.org/10.1038/bjc.1991.400"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00170863", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030651522", 
              "https://doi.org/10.1007/bf00170863"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-74760-1_4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007428318", 
              "https://doi.org/10.1007/978-3-642-74760-1_4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00451646", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007973771", 
              "https://doi.org/10.1007/bf00451646"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00390468", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013794152", 
              "https://doi.org/10.1007/bf00390468"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/3-540-50130-4_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035090550", 
              "https://doi.org/10.1007/3-540-50130-4_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00208894", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016124729", 
              "https://doi.org/10.1007/bf00208894"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00254100", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005434710", 
              "https://doi.org/10.1007/bf00254100"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00304762", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042766005", 
              "https://doi.org/10.1007/bf00304762"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00261487", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020513223", 
              "https://doi.org/10.1007/bf00261487"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-74760-1_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023505644", 
              "https://doi.org/10.1007/978-3-642-74760-1_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00391500", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027752482", 
              "https://doi.org/10.1007/bf00391500"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00389240", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022263549", 
              "https://doi.org/10.1007/bf00389240"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00179436", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009220875", 
              "https://doi.org/10.1007/bf00179436"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00686004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001888094", 
              "https://doi.org/10.1007/bf00686004"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-199142020-00007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014786815", 
              "https://doi.org/10.2165/00003495-199142020-00007"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00390038", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000317726", 
              "https://doi.org/10.1007/bf00390038"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/3-540-54261-2_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013117148", 
              "https://doi.org/10.1007/3-540-54261-2_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-74760-1_6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043493597", 
              "https://doi.org/10.1007/978-3-642-74760-1_6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/3-540-50130-4_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035442208", 
              "https://doi.org/10.1007/3-540-50130-4_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-94-011-1252-9_6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006481172", 
              "https://doi.org/10.1007/978-94-011-1252-9_6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1994-08", 
        "datePublishedReg": "1994-08-01", 
        "description": "The earliest reports on the therapeutic use of metals or metal-containing compounds in cancer and leukemia date from the sixteenth and nineteenth centuries. They were forgotten until the 1960s, when the antitumour activity of the inorganic complex cis-diammine-dichloroplatinum(II) (cisplatin) was discovered. This led to the development of other types of non-organic cytostatic drugs.Cisplatin has developed into one of the most frequently used and most effective cytostatic drugs for the treatment of solid carcinomas. Numerous other metal compounds containing platinum, other platinum metals, and even non-platinum metals were then shown to be effective against tumours in man and experimental tumours in animals. These compounds comprise main-group metallic compounds of gallium, germanium, tin, and bismuth, early-transition metal complexes of titanium, vanadium, niobium, molybdenum, and rhenium, and late-transition metal complexes of ruthenium, rhodium, iridium, platinum, copper, and gold.Several platinum complexes and four non-platinum-metal antitumour agents have so far entered early clinical trials. Gallium trinitrate and spirogermanium have already passed phase II clinical studies and have shown limited cytostatic activity against certain human carcinomas and lymphomas. The two early-transition metal complexes budotitane and titanocene dichloride have just reached the end of phase I clinical trials and have been found to have an unusual pattern of organ toxicity in man. Titanocene dichloride will soon enter phase II clinical studies.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf00193472", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1054337", 
            "issn": [
              "0031-6970", 
              "1432-1041"
            ], 
            "name": "European Journal of Clinical Pharmacology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "47"
          }
        ], 
        "keywords": [
          "metal complexes", 
          "titanocene dichloride", 
          "late transition metal complexes", 
          "early transition metal complexes", 
          "complexes of metals", 
          "non-platinum metals", 
          "metal-containing compounds", 
          "platinum complexes", 
          "metal compounds", 
          "platinum metals", 
          "antitumour agents", 
          "metallic compounds", 
          "platinum", 
          "compounds", 
          "complexes", 
          "dichloride", 
          "metals", 
          "cytostatic activity", 
          "effective cytostatic drugs", 
          "ruthenium", 
          "rhodium", 
          "budotitane", 
          "cytostatic drugs", 
          "iridium", 
          "antitumour activity", 
          "rhenium", 
          "vanadium", 
          "molybdenum", 
          "gold", 
          "copper", 
          "certain human carcinomas", 
          "niobium", 
          "gallium", 
          "tin", 
          "titanium", 
          "agents", 
          "drugs", 
          "activity", 
          "organ toxicity", 
          "toxicity", 
          "germanium", 
          "earlier reports", 
          "therapeutic use", 
          "cisplatin", 
          "spirogermanium", 
          "study", 
          "phase I clinical trial", 
          "types", 
          "use", 
          "development", 
          "experimental tumors", 
          "trinitrate", 
          "treatment", 
          "II clinical study", 
          "date", 
          "phase II clinical study", 
          "patterns", 
          "end", 
          "report", 
          "human carcinomas", 
          "early clinical trials", 
          "clinical studies", 
          "solid carcinomas", 
          "unusual pattern", 
          "cancer", 
          "clinical trials", 
          "century", 
          "tumors", 
          "animals", 
          "nineteenth century", 
          "trials", 
          "carcinoma", 
          "lymphoma", 
          "men"
        ], 
        "name": "Complexes of metals other than platinum as antitumour agents", 
        "pagination": "1-16", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1007044066"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf00193472"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "7988618"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf00193472", 
          "https://app.dimensions.ai/details/publication/pub.1007044066"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:51", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_240.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf00193472"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00193472'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00193472'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00193472'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00193472'


     

    This table displays all metadata directly associated to this object as RDF triples.

    255 TRIPLES      21 PREDICATES      130 URIs      99 LITERALS      14 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf00193472 schema:about N0a4ee9605f174df691b7d6007a262983
    2 N122474ecfac3498b97805e7f9aa54739
    3 N29a7e524d4504da684d100eddbdc6fdc
    4 N3e73a881661b45f496ec3588f43a1678
    5 Nb0a5aead34f24f8987517062b217fc9c
    6 Nc9e544a8db7d410b96517a36c87fb112
    7 Nd278f7e011c044c790169bdcf5c9aca7
    8 anzsrc-for:11
    9 anzsrc-for:1115
    10 schema:author N08a814b41d07411bb01789d90f006ed7
    11 schema:citation sg:pub.10.1007/3-540-50130-4_2
    12 sg:pub.10.1007/3-540-50130-4_3
    13 sg:pub.10.1007/3-540-54261-2_2
    14 sg:pub.10.1007/978-3-642-74760-1_2
    15 sg:pub.10.1007/978-3-642-74760-1_4
    16 sg:pub.10.1007/978-3-642-74760-1_6
    17 sg:pub.10.1007/978-94-011-1252-9_6
    18 sg:pub.10.1007/bf00170863
    19 sg:pub.10.1007/bf00179436
    20 sg:pub.10.1007/bf00208894
    21 sg:pub.10.1007/bf00254100
    22 sg:pub.10.1007/bf00261487
    23 sg:pub.10.1007/bf00304762
    24 sg:pub.10.1007/bf00389240
    25 sg:pub.10.1007/bf00390038
    26 sg:pub.10.1007/bf00390468
    27 sg:pub.10.1007/bf00391500
    28 sg:pub.10.1007/bf00451646
    29 sg:pub.10.1007/bf00686004
    30 sg:pub.10.1007/bf01410137
    31 sg:pub.10.1038/222385a0
    32 sg:pub.10.1038/bjc.1991.400
    33 sg:pub.10.2165/00003495-199142020-00007
    34 schema:datePublished 1994-08
    35 schema:datePublishedReg 1994-08-01
    36 schema:description The earliest reports on the therapeutic use of metals or metal-containing compounds in cancer and leukemia date from the sixteenth and nineteenth centuries. They were forgotten until the 1960s, when the antitumour activity of the inorganic complex cis-diammine-dichloroplatinum(II) (cisplatin) was discovered. This led to the development of other types of non-organic cytostatic drugs.Cisplatin has developed into one of the most frequently used and most effective cytostatic drugs for the treatment of solid carcinomas. Numerous other metal compounds containing platinum, other platinum metals, and even non-platinum metals were then shown to be effective against tumours in man and experimental tumours in animals. These compounds comprise main-group metallic compounds of gallium, germanium, tin, and bismuth, early-transition metal complexes of titanium, vanadium, niobium, molybdenum, and rhenium, and late-transition metal complexes of ruthenium, rhodium, iridium, platinum, copper, and gold.Several platinum complexes and four non-platinum-metal antitumour agents have so far entered early clinical trials. Gallium trinitrate and spirogermanium have already passed phase II clinical studies and have shown limited cytostatic activity against certain human carcinomas and lymphomas. The two early-transition metal complexes budotitane and titanocene dichloride have just reached the end of phase I clinical trials and have been found to have an unusual pattern of organ toxicity in man. Titanocene dichloride will soon enter phase II clinical studies.
    37 schema:genre article
    38 schema:isAccessibleForFree false
    39 schema:isPartOf N7173f192670e4f1a9380f6ef5d0d1f10
    40 Ne3e79815fc51406ab58dc5d27381b839
    41 sg:journal.1054337
    42 schema:keywords II clinical study
    43 activity
    44 agents
    45 animals
    46 antitumour activity
    47 antitumour agents
    48 budotitane
    49 cancer
    50 carcinoma
    51 century
    52 certain human carcinomas
    53 cisplatin
    54 clinical studies
    55 clinical trials
    56 complexes
    57 complexes of metals
    58 compounds
    59 copper
    60 cytostatic activity
    61 cytostatic drugs
    62 date
    63 development
    64 dichloride
    65 drugs
    66 earlier reports
    67 early clinical trials
    68 early transition metal complexes
    69 effective cytostatic drugs
    70 end
    71 experimental tumors
    72 gallium
    73 germanium
    74 gold
    75 human carcinomas
    76 iridium
    77 late transition metal complexes
    78 lymphoma
    79 men
    80 metal complexes
    81 metal compounds
    82 metal-containing compounds
    83 metallic compounds
    84 metals
    85 molybdenum
    86 nineteenth century
    87 niobium
    88 non-platinum metals
    89 organ toxicity
    90 patterns
    91 phase I clinical trial
    92 phase II clinical study
    93 platinum
    94 platinum complexes
    95 platinum metals
    96 report
    97 rhenium
    98 rhodium
    99 ruthenium
    100 solid carcinomas
    101 spirogermanium
    102 study
    103 therapeutic use
    104 tin
    105 titanium
    106 titanocene dichloride
    107 toxicity
    108 treatment
    109 trials
    110 trinitrate
    111 tumors
    112 types
    113 unusual pattern
    114 use
    115 vanadium
    116 schema:name Complexes of metals other than platinum as antitumour agents
    117 schema:pagination 1-16
    118 schema:productId N2ceb949ebe104788852486c9cd26e34f
    119 N70476eeb443246dcb75b1baeea0ce62e
    120 N8a9ac8050b4248c78ac888790f702248
    121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007044066
    122 https://doi.org/10.1007/bf00193472
    123 schema:sdDatePublished 2022-08-04T16:51
    124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    125 schema:sdPublisher N852a6abf652d4a1491875349b3c1f580
    126 schema:url https://doi.org/10.1007/bf00193472
    127 sgo:license sg:explorer/license/
    128 sgo:sdDataset articles
    129 rdf:type schema:ScholarlyArticle
    130 N08a814b41d07411bb01789d90f006ed7 rdf:first sg:person.0113514530.30
    131 rdf:rest rdf:nil
    132 N0a4ee9605f174df691b7d6007a262983 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name In Vitro Techniques
    134 rdf:type schema:DefinedTerm
    135 N122474ecfac3498b97805e7f9aa54739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Antineoplastic Agents
    137 rdf:type schema:DefinedTerm
    138 N29a7e524d4504da684d100eddbdc6fdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Animals
    140 rdf:type schema:DefinedTerm
    141 N2ceb949ebe104788852486c9cd26e34f schema:name pubmed_id
    142 schema:value 7988618
    143 rdf:type schema:PropertyValue
    144 N3e73a881661b45f496ec3588f43a1678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Clinical Trials, Phase I as Topic
    146 rdf:type schema:DefinedTerm
    147 N70476eeb443246dcb75b1baeea0ce62e schema:name dimensions_id
    148 schema:value pub.1007044066
    149 rdf:type schema:PropertyValue
    150 N7173f192670e4f1a9380f6ef5d0d1f10 schema:issueNumber 1
    151 rdf:type schema:PublicationIssue
    152 N852a6abf652d4a1491875349b3c1f580 schema:name Springer Nature - SN SciGraph project
    153 rdf:type schema:Organization
    154 N8a9ac8050b4248c78ac888790f702248 schema:name doi
    155 schema:value 10.1007/bf00193472
    156 rdf:type schema:PropertyValue
    157 Nb0a5aead34f24f8987517062b217fc9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Humans
    159 rdf:type schema:DefinedTerm
    160 Nc9e544a8db7d410b96517a36c87fb112 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Clinical Trials, Phase II as Topic
    162 rdf:type schema:DefinedTerm
    163 Nd278f7e011c044c790169bdcf5c9aca7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Metals
    165 rdf:type schema:DefinedTerm
    166 Ne3e79815fc51406ab58dc5d27381b839 schema:volumeNumber 47
    167 rdf:type schema:PublicationVolume
    168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    169 schema:name Medical and Health Sciences
    170 rdf:type schema:DefinedTerm
    171 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    172 schema:name Pharmacology and Pharmaceutical Sciences
    173 rdf:type schema:DefinedTerm
    174 sg:journal.1054337 schema:issn 0031-6970
    175 1432-1041
    176 schema:name European Journal of Clinical Pharmacology
    177 schema:publisher Springer Nature
    178 rdf:type schema:Periodical
    179 sg:person.0113514530.30 schema:affiliation grid-institutes:grid.14095.39
    180 schema:familyName Köpf-Maier
    181 schema:givenName P.
    182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0113514530.30
    183 rdf:type schema:Person
    184 sg:pub.10.1007/3-540-50130-4_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035442208
    185 https://doi.org/10.1007/3-540-50130-4_2
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1007/3-540-50130-4_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035090550
    188 https://doi.org/10.1007/3-540-50130-4_3
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1007/3-540-54261-2_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013117148
    191 https://doi.org/10.1007/3-540-54261-2_2
    192 rdf:type schema:CreativeWork
    193 sg:pub.10.1007/978-3-642-74760-1_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023505644
    194 https://doi.org/10.1007/978-3-642-74760-1_2
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/978-3-642-74760-1_4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007428318
    197 https://doi.org/10.1007/978-3-642-74760-1_4
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1007/978-3-642-74760-1_6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043493597
    200 https://doi.org/10.1007/978-3-642-74760-1_6
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1007/978-94-011-1252-9_6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006481172
    203 https://doi.org/10.1007/978-94-011-1252-9_6
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1007/bf00170863 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030651522
    206 https://doi.org/10.1007/bf00170863
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1007/bf00179436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009220875
    209 https://doi.org/10.1007/bf00179436
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1007/bf00208894 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016124729
    212 https://doi.org/10.1007/bf00208894
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1007/bf00254100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005434710
    215 https://doi.org/10.1007/bf00254100
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1007/bf00261487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020513223
    218 https://doi.org/10.1007/bf00261487
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1007/bf00304762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042766005
    221 https://doi.org/10.1007/bf00304762
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1007/bf00389240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022263549
    224 https://doi.org/10.1007/bf00389240
    225 rdf:type schema:CreativeWork
    226 sg:pub.10.1007/bf00390038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000317726
    227 https://doi.org/10.1007/bf00390038
    228 rdf:type schema:CreativeWork
    229 sg:pub.10.1007/bf00390468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013794152
    230 https://doi.org/10.1007/bf00390468
    231 rdf:type schema:CreativeWork
    232 sg:pub.10.1007/bf00391500 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027752482
    233 https://doi.org/10.1007/bf00391500
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1007/bf00451646 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007973771
    236 https://doi.org/10.1007/bf00451646
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1007/bf00686004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001888094
    239 https://doi.org/10.1007/bf00686004
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1007/bf01410137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041980973
    242 https://doi.org/10.1007/bf01410137
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1038/222385a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001455608
    245 https://doi.org/10.1038/222385a0
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/bjc.1991.400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015978323
    248 https://doi.org/10.1038/bjc.1991.400
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.2165/00003495-199142020-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014786815
    251 https://doi.org/10.2165/00003495-199142020-00007
    252 rdf:type schema:CreativeWork
    253 grid-institutes:grid.14095.39 schema:alternateName Institut für Anatomie, Freie Universität Berlin, D-14195, Berlin-Dahlem, Germany
    254 schema:name Institut für Anatomie, Freie Universität Berlin, D-14195, Berlin-Dahlem, Germany
    255 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...